Liver fibrosis

M. Merve Aydın¹ Kamil Can Akçalı²

¹Mikrogen Genetic Diagnostic Laboratory, Ankara, Turkey ²Department of Biophysics, Ankara University, School of Medicine, Ankara, Turkey

Cite this article as: Aydın MM, Akçalı KC. Liver fibrosis. Turk J Gastroenterol 2018; 29: 14-21.

Abstract

Liver fibrosis is a wound-healing response generated against an insult to the liver that causes liver injury. It has the potential to progress into cirrhosis, and if not prevented, it may lead to liver cancer and liver failure. The activation of hepatic stellate cells (HSCs) is the central event underlying liver fibrosis. In addition to HSCs, numerous studies have supported the potential contribution of bone marrow-derived cells and myofibroblasts to liver fibrosis. The liver is a heterogeneous organ; thus, molecular and cellular events that underlie liver fibro-genesis are complex. This review aims to focus on major events that occur during liver fibrogenesis. In addition, important antifibrotic therapeutic approaches and experimental liver fibrosis models will be discussed.

Keywords: Fibrosis, liver, MMPs, experimental models

INTRODUCTION

Liver fibrosis is a response generated as a result of chronic liver injury due to various factors, such as alcohol consumption, non-alcoholic steatohepatitis (NASH), viral hepatitis [hepatitis B (HBV) and hepatitis C], autoimmune hepatitis, non-alcoholic fatty liver disease (NAFLD), and cholestatic liver diseases. The common effect of all of these factors on the liver is the generation of a chronic inflammation resulting in an abnormal wound healing response. Different cell types and mediators participate to encapsulate injury. The generation of a fibrotic response in the liver gives rise to the accumulation of extracellular matrix (ECM) components, leading to fibrous scar formation (1,2). The architecture of the liver is disrupted by the presence of a fibrous scar, which causes hepatocyte loss and the deregulation of the normal functioning of the liver, ultimately resulting in liver failure (3). Liver fibrosis is a reversible process, unless it is progressive and leads to cirrhosis. The removal of the fibrotic response-causing agent aids in the regression of fibrosis as long as the liver is not at the stage of advanced cirrhosis (4,5).

Pathogenesis of liver fibrosis

Liver fibrosis is a serious health problem. If not treated, it may lead to advanced liver cirrhosis and hepatocellular carcinoma (HCC). Fibrogenesis is initiated by myofibroblast activation and proliferation because activated myofibroblasts are the major source of ECM in the injured liver (2,3). Although activated hepatic stellate cells (aHSCs) are the major source of myofibroblasts in the fibrotic liver, they are not the only precursors. Endogenous portal fibroblasts, fibrocytes, bone marrow-derived cells, and liver parenchymal cell-derived myofibroblasts that undergo epithelial-mesenchymal transition (EMT) give rise to a significant percent of myofibroblasts in the fibrotic liver. Different cell types activate myofibroblasts depending on the etiology of liver fibrosis (6). A previous study demonstrated that aHSCs are the source of myofibroblasts in a carbon tetrachloride (CCl₄)-induced liver fibrosis model, whereas portal fibroblasts give rise to myofibroblasts in the cholestatic liver (6). Bone marrow-derived cells represent a substantial fraction of the total fibrogenic population in a more chronic injury.

In the quiescent state, HSCs are known as quiescent HSCs (qHSCs), and they are responsible for the storage of vitamin A in the liver. As a result of liver injury, qHSCs are activated by inflammatory mediators, which in turn differentiate into myofibroblasts (7). In this way, tissue remodeling is initiated in the liver by the secretion of ECM proteins and matrix metalloproteinases (MMPs) by aHSCs (8,9).

Cellular and physiological events in liver fibrosis

Mechanisms of liver fibrosis

Different factors, including toxins, hepatitis, steatohepatitis, and autoimmune disorders, promote the activation of HSCs, which in turn acquire a myofibroblast-like phenotype (2). HSC activation comprises two major phases,

Address for Correspondence: Kamil Can Akçalı E-mail: akcali@ankara.edu.tr

Received: May, 28, 2017 Accepted: October 3, 2017

© Copyright 2018 by The Turkish Society of Gastroenterology · Available online at www.turkjgastroenterol.org DOI: 10.5152/tjg.2018.17330

namely, initiation and perpetuation, and these processes are followed by a final resolution phase in case the injury cause still exists (10). Soon after the injury, the initiation phase commences to generate a response against the factors that cause injury at the gene expression level, resulting in phenotypic changes. Early activation is driven by the initial paracrine stimulation and presence of damaged hepatocyte products, causing priming of the cells for activation. Continuous stimuli for activation result in perpetuation that is mainly based on the activity of primed cells for activation. Cell behavior, such as proliferation, fibrogenesis, contractility, matrix degradation, chemotaxis, retinoid loss, and cytokine release, changes as a result of this continuous activation. Overall, these changes contribute to the accumulation of ECM. HSCs undergo apoptosis, senescence, or become quiescent in the case of fibrosis resolution (11). Several studies have shown that different pathways and numerous cell-cell interactions control fibrogenesis and fibrosis regression (Table 1).

Among the mechanisms of liver fibrogenesis, growth factor signaling has a significant role in the activation of HSCs, mainly through platelet-derived growth factor (PDGF) signaling. Cellular proliferation is initiated when PDGF recognizes its receptors that promote the dimerization of receptor subunits and autophosphorylation. This process initiates Ras-mitogen-activated protein kinase pathway activation, increases intracellular calcium, and results in protein kinase C activation (12,13). The paramount importance of PDGF signaling has been shown after blocking with PDGF receptor inhibitors, which may be a promising potential target for drug development. In animal models, this approach has been shown to result in antifibrotic activity during fibrosis (14). HSC proliferation is also stimulated by growth factors, such as transforming growth factor (TGF)-a and epidermal growth factor (15-16). Hepatic angiogenesis is initiated by the recognition of vascular endothelial growth factor (VEGF) by its receptors. Overall, these growth factors promote the remodeling of ECM, resulting in collagen formation (17).

In the normal liver, collagens IV and VI are present in the space of Disse. However, during fibrogenesis, they are replaced by collagens I and II and fibronectin (18). Normally, TGF- β 1 is found inactive, but following activation, it initiates a signaling pathway through Smad proteins, resulting in collagen production. Moreover, TGF- β 1 promotes the transdifferentiation of quiescent HSCs into myofibroblasts that secrete ECM (19). In addition, leptin signaling also contributes to fibrogenesis through TGF- β 1. Kupffer cells have been shown to release TGF- β 1 following liver injury, which is a downstream event of leptin signaling initiation (20).

HSCs are capable of expressing different chemokine receptors; such as CXC chemokine receptor (CXCR) 3; C-C chemokine receptor (CCR) 5; CCR7; and ligands, including chemokine ligand (CCL) 2, CCL3, CCL5, CXC chemokine ligand (CXCL) 1, CXCL8, CXCL9, and CXCL10. Chemokines are a class of small chemotactic molecules that regulate inflammation. Even though the role of each specific chemokine in liver fibrogenesis is still being studied, the migration ability of fibrogenic cells to the injury site is known to be promoted by chemokines, thus increasing the number of cells and inflammation at the site of injury. Both profibrogenic and antifibrogenic effects occur on interaction between chemokine receptors and ligands. CCR5, CCR1, and CXCL4 cause fibrosis, whereas the interaction of CXCL9 and CXCR3 protects against fibrosis (21-23).

Adipokines are another major player during liver fibrogenesis (24). They are secreted from adipose tissue. One of them, leptin, is a well-known circulating adipogenic hormone that has the ability to promote fibrogenesis.

Table 1	Maior	signaling	nathways and	d effectors	in liver	fibrosis
I ADIC I	. Major	Signaling	pathways and		III IIVEI	11010515

 Pathway	Effectors		
Growth factor signaling	PDGF, TGF-α, EGF, VEGF		
Fibrogenic signaling pathway	TGF-β1		
Chemokine pathways	CCR5, CCR1, CXCL4, CXCL9, CXCR3		
Adipokine pathways	Leptin, adiponectin		
Neuroendocrine pathways	Cannabinoid and opioid signaling, thyroid hormones, serotonin		
CCR: C-C chemokine receptor; CXCL: CXC growth factor; TGF: transforming growth fa	chemokine ligand; CXCR: CXC chemokine receptor; EGF: epidermal growth factor; PDGF: platelet-derived .ctor; VEGF: vascular endothelial growth factor		

15

Circulating leptin in the blood is proportional to the adipose mass in the body, and increased levels of leptin in the body are associated with fibrogenesis (25,26). In contrast, adiponectin as a counter-regulatory hormone has been suggested to have antifibrogenic activity, which is partially confirmed with the finding that adiponectin expression decreases during hepatic fibrogenesis (27).

Neurochemical and neurotrophic factors also have effects on HSCs and thus during liver fibrosis. Liver injury induces the up-regulation of the neuroendocrine system, and activated HSCs start to express receptors that regulate cannabinoid (CB) signaling (28). CB1 signaling has been known to promote hepatic fibrogenesis, whereas CB2 signaling has an antifibrotic effect (29). Moreover, other neurotrophic factors also contribute to fibrosis, such as opioid signaling that promotes HSC proliferation and collagen production (30). Additionally, thyroid hormones are known to increase HSC activation, whereas serotonin is pro-fibrotic (31,32).

Inflammatory pathways play a significant role in liver fibrogenesis. There is a positive feedback loop between inflammatory and fibrogenic cells, which in turn results in amplified fibrosis. The activation of HSCs is promoted with many other cell types, such as natural killer (NK) cells, T cells, Kupffer cells, macrophages, dendritic cells, and endothelial cells (23). Bacterial lipopolysaccharide is a well-known fibrosis-promoting agent by the activation of Toll-like receptor (TLR) 4 signaling, which is expressed on macrophages and HSCs (33,34). In contrast, Kupffer cell activity increases the activity of nuclear factor-kappa β , which in turn promotes pro-inflammatory cytokine secretion (35).

Oxidative stress and apoptotic cells are capable of inducing an immune response (36,37). Liver injury results in the apoptosis of cells, which are phagocytosed by HSCs, resulting in increased nicotinamide adenine dinucleotide phosphate oxidase and cell survival (38,39). In contrast, apoptotic hepatocyte DNA was demonstrated to interact with TLR9 on HSCs, resulting in the activation of TRL9, thus increasing collagen production and HSC migration (40). Finally, activated HSCs are killed by NK cells, demonstrating an antifibrotic effect by inducing HSC apoptosis (41).

Hepatic fibrosis is based on the wound-healing response, wherein angiogenesis has a significant role in liver regen-

eration. Because angiogenesis is known to promote liver carcinogenesis, the balance among angiogenic factors should be finely regulated (42). HSCs are located in the perisinusoidal space and regulate intrahepatic blood flow with the aid of their contractile abilities (43). Progressive liver injury results in the formation of vascular disorganization in certain areas, resulting in hypoxia, initiating angiogenesis. A hypoxic environment induces VEGF and PDGF cytokine activities that promote both fibrogenic and angiogenic responses (42). Activated HSCs by hypoxia initiate interactions with PDGF and VEGF signaling, which play an important role in angiogenesis (23).

Reversibility of liver fibrosis

The reversibility of liver fibrosis was a controversial issue for a long time because some of the earlier studies argued that liver fibrosis is irreversible. However, more recent studies have supported the idea that it is a reversible process if the injury-causing stimulus is withdrawn and demonstrated this argument in both experimental liver fibrosis models and clinical samples of a cirrhotic human liver (44-46). With the withdrawal of the causative agent, a cascade of events occurs to initiate the reversion of the fibrotic response. A decrease in cytokine levels, the loss of fibrous scars and myofibroblasts through senescence and apoptosis, and an increase in the collagenase activity are the initial events that occur during the reversion of liver fibrosis (47,48).

Moreover, the loss of myofibroblasts results in a decrease in tissue inhibitors of metalloproteinase (TIMP) levels and an increase in MMP activity, thus degrading ECM (49). MMPs are calcium-dependent enzymes that specifically degrade collagens and non-collagenous ECM substrates (50). Stellate cells secrete basement membrane proteases, MMP-2, MMP-9, and stromelysin (MMP-3), and interstitial collagenase, MMP-13 (50). The inactivation of proteases by binding to TIMPs is also emerging as an important locus of control because the sustained production of these proteins during liver injury could inhibit the activity of interstitial collagenases, leading to reduced degradation of the accumulating matrix (50). In addition, TIMP-1 is anti-apoptotic for stellate cells, which may result in an increased number of activated stellate cells (50).

The loss of myofibroblasts is not the only component of liver fibrosis regression. Macrophages that have a significant role in the progression and resolution of liver fibrosis by producing cytokines and chemokines to induce HSC transition into ECM-myofibroblasts are also crucial for liver fibrosis regression (51,52). During the progression of liver fibrosis, macrophages augment fibrogenesis, whereas during resolution through the increased production of MMP-13, matrix degradation is increased (52).

Senescence in liver fibrosis

HSCs are observed at the senescence state in the cirrhotic liver, a state in which they stay non-proliferative, lack a collagen-producing capacity, and produce more inflammatory cytokines (53). A previous study demonstrated that p53 has a role in the restriction of liver fibrosis development through its association with cellular senescence via p21 induction (54). Moreover, in another study, the expression of p53 in the senescent HSCs was shown to have an association with the inhibition of HCC development (55). In contrast, another study has claimed that the senescence-associated secretory phenotype in HSCs induces the development of obesity-associated HCC (56). Thus, the role of HSC senescence in liver fibrosis remains controversial and needs more findings.

Autophagy in liver fibrosis

Autophagy is a cellular event that occurs to maintain cellular homeostasis by degrading damaged organelles and protein aggregates, which is also observed in HSC activation, and the inhibition of autophagy has been demonstrated to suppress HSC proliferation and activation (57). In contrast, other studies have shown that the induction of autophagy in hepatocytes aids in the treatment of some other liver diseases, such as α 1 anti-trypsin deficiency, NASH, and alcoholic liver disease (58).

Angiogenesis and liver fibrosis

Angiogenesis is the formation of new blood vessels, which is induced by hypoxia in several organs. In addition to its contribution to tumor growth progression, angiogenesis is crucial for the growth and repair of injured tissues. Moreover, angiogenesis has a role in the pathogenesis of several inflammatory diseases (59-61). Although angiogenesis occurs in various organs in the body, it is a more complex process in the liver. Angiogenesis initiated by chronic liver injury is based on different factors; hypoxia caused by inflammation and fibrosis and wound healing initiated by increased cytokine and growth factor levels. Several studies claim that anti-angiogenic therapy without blocking the wound-healing response is important for the prevention of liver fibrosis (62-64).

EMT in liver fibrosis

Initially, EMT was suggested to contribute to liver fibrosis by generating collagen-producing myofibroblasts. However, this finding has become another controversial issue in liver fibrosis owing to opposite findings regarding the role of EMT in this process (65). One of the reasons for the opposite findings on EMT and liver fibrosis is that lineage tracing is an experimental technique that has pitfalls, such as Cre-mediated recombination is not 100% efficient and the number of markers analyzed to detect the presence of EMT may not be adequate. Furthermore, similar to many other studies, experimental liver fibrosis models may not completely reflect the actual EMT that occurs during chronic human liver diseases.

Experimental liver fibrosis models

In vivo models of liver fibrosis

Chemical-based models

Various chemical agents are used to induce liver fibrosis in animal models with different methods of administration. Intraperitoneal (i.p.) injection is the fastest way to trigger liver fibrosis. In contrast, oral administration or inhalation-based administration is also used, but it takes more time than i.p. injection. In any case, chemical-based liver fibrosis models are frequently used because they are easily replicable (66,67).

Ethanol is one of the frequently used chemicals to study liver fibrosis because alcohol consumption is among the causes of chronic liver diseases worldwide. Ethanol administration induces the activation of HSCs, the apoptosis of hepatocytes, and inflammation (68). CCl₄ is a well-known hepatotoxin that is popular in liver fibrosis and cirrhosis studies in rodents. This model effectively mimics liver fibrosis induced by toxic damage. Although the i.p. injection of CCl₄ is widespread, it can also be administered subcutaneously, orally, or via inhalation. Thioacetamide is another chemical agent that is similar to CCl_4 in the way that both need to be metabolically activated to be toxic. The outcome of thioacetamide administration has been found to be high oxidative damage associated with the activation of HSCs (69). Dimethylnitrosamine (DMN) and diethylnitrosamine (DEN) are other chemicals that are carcinogenic and frequently preferred to generate liver fibrosis models in animals. The biotransformation of DMN and DEN generates reactive oxygen species, which in turn react with nucleic acids, lipids, and proteins, resulting in cellular malfunction and necrosis (70-73).

Diet-based models

Even though it is possible to induce NAFLD progression to NASH using certain diets in experimental animals, these models do not completely mimic the human pathology (74). A model was found to mimic hepatic stress due to fatty acid transition from the adipose tissue to the liver and increased triglyceride production (75). A methionineand choline-deficient (MCD) diet is preferred for NASH studies, but this model ignores obesity and insulin-resistance problems (76). MCD diet problems are overcome by a high-fat (HF) diet because it induces insulin resistance and an increase in body weight. A HF diet model is very similar to human NASH but requires a very long time to develop in animals. An alternative high-cholesterol diet was proposed, but this also has the disadvantage of a lack of obesity and insulin resistance (77). A choline-deficient L-amino acid-defined diet is similar to the MCD diet, but in addition, it induces obesity and insulin resistance. In the long term, this model is important for NAFLD, NASH, and HCC studies because it promotes liver tumor formation associated with liver fibrosis (78).

Surgery-based models

Bile duct ligation (BDL) is the most common surgery-based model that induces biliary fibrosis and cholestatic injury, which is based on the double ligation of the bile duct (79). In this way, increased biliary pressure is generated together with inflammation and cytokine secretion, resulting in cholestasis and liver damage. The applicability and replicability of BDL are not high, and this model has been suggested for use in short-term liver fibrosis studies associated with cholestasis (80).

Genetically modified models

The use of genetically modified animals in liver fibrosis studies has both advantages and disadvantages. It allows researchers to investigate specific proteins and signaling pathways underlying liver fibrosis, but on the other hand, it is hard to develop liver fibrosis in these animals without a second stimulus (81-83). In multidrug resistance-associated protein 2-deficient mice, a high level of hepatocyte necrosis and portal inflammation, a strong human cholangitis-like phenotype, and periductal fibrosis have been observed (84). Moreover, these mice were found to be capable of developing biliary fibrosis at 4-8 weeks and HCC at 4-6 months (84). *Alms1Fat ausi* mutant mice

form another group of genetically modified animals for liver fibrosis studies because of the effect of both diet and genetics on liver fibrosis progression in these mice. They are ideal for studies investigating NAFLD progression to NASH (85).

Infection-based models

In humans, hepatitis virus induces liver fibrosis, but it is not the case in rodents. Thus, genetically engineered animals that are capable of expressing the HBV envelope-coding region under the control of the albumin promoter are frequently used for hepatitis studies (86). The use of immunodeficient mice transfected with the HBV plasmid is an alternative for these animals (87). In addition to these viral infection-based models, different parasite infection-based models are used to study chronic liver diseases (66). Overall, all of these infection-based models aim to increase the cytokine levels, resulting in the activation of HSCs and liver fibrosis.

In vitro models of Liver Fibrosis

Although in vivo models are more effective in reflecting the actual hepatic environment, in vitro models are also frequently used in liver studies. Primary HSCs isolated from the liver are good models for this, but a low viability of these cells after isolation is a common problem. Moreover, HSCs are activated just after they are embedded on a culture dish, which does not reflect the real mechanism underlying liver fibrogenesis. Obtaining pure HSCs is another problem for liver fibrosis studies because HSC cultures may be easily contaminated with other liver cell types. Cell lines are used as an alternative for primary cells, but like in many other studies, they do not completely reflect the in vivo scenario in the liver, even though they are easily available and unlimited (66).

ANTIFIBROTIC THERAPIES

Thanks to continued experimental advances in the past years, new promising and exciting therapeutic approaches can be developed. One of the active research areas to develop new therapy is toward targeting fibrogenic events in the liver.

TGF- β 1 is a well-known molecule that occurs in fibrotic events in all organs. However, its systemic inhibition may increase overall inflammation. Thus, targeting certain steps in the activation of TGF- β 1 may be helpful to decrease the fibrotic response in the liver. Integrins and connective tissue growth factor are good candidates for targeting the TGF- β 1 pathway because they play significant roles in TGF- β 1 release and activation, respectively (88, 89). A study has demonstrated that cannabinoid receptor 1 (CB1) deactivation attenuates experimental liver fibrosis, but an antagonist of CB1 was shown to have side effects in another study. Reducing redox injury is another alternative for antifibrotic therapy, such as the use of antioxidants. Unfortunately, owing to differences between animals and humans, testing the effect of antioxidants on liver fibrosis is more complex than predicted, and more clinical trials need to be conducted (90).

Another possible area to develop new therapies is in the targeting of fibrosis reversal. In this context, targeting macrophage recruitment may be a useful approach in rodents because it is central in fibrogenesis and its regression. However, because macrophage subpopulations in humans have not been clearly characterized yet, macrophage-targeting studies would not be helpful, until human macrophage biology is completely understood (90).

Liver fibrosis is a dynamic process; thus, targeting one pathway in this process may not be enough to induce its reversal. Combination therapies that target the central components that underlie liver fibrosis are important, such as ECM and certain cell types that play roles in this process. Overall, combination approaches for antifibrotic therapies are very encouraging. However, toxic and off-target effects of these combination therapies should not be ignored in future studies, like in many other therapeutic approaches for different diseases.

Peer-review: Externally peer-reviewed.

Author contributions: Concept - K.C.A.; Literature Search - M.M.A., K.C.A.; Writing - M.M.A., K.C.A.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study has received no financial support.

REFERENCES

1. Sun M, Kisseleva T. Reversibility of liver fibrosis. Clin Res Hepatol Gastroenterol 2015; 39 Suppl 1:S 60-3.

2. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-18. [CrossRef]

3. Kisseleva T, Brenner DA. Mechanisms of fibrogenesis. Exp Biol Med 2008; 233: 109-22. [CrossRef]

4. Ekihiro S, Brenner DA. Recent advancement of molecular mecha-

nisms of liver fibrosis. J Hepatobiliary Pancreat Sci 2015; 22: 512-8. [CrossRef]

5. Brenner DA. Reversibility of liver fibrosis. Gastroenterol Hepatol (N Y) 2013; 9: 737-9.

6. Iwaisako K, Jiang C, Zhang M, et al. Origin of myofibroblasts in the fibrotic liver in mice. Proc Natl Acad Sci U S A 2014; 111: E3297-305. [CrossRef]

7. Zhang CY, Yuan WG, He P, Lei JH, Wang CX. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets World J Gastroenterol 2016; 22: 10512-22. [CrossRef]

8. Li D, He L, Guo H, Chen H, Shan H. Targeting activated hepatic stellate cells (aHSCs) for liver fibrosis imaging. EJNMMI Res 2015; 5: 71. [CrossRef]

9. Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver fibrosis. Compr Physiol 2013; 3: 1473-92. [CrossRef]

10. Friedman SL. Mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 2004: 98-105. [CrossRef]

11. Krizhanovsky V, Yon M, Dickins RA, et al. Senescence of activated stellate cells limits liver fibrosis. Cell 2008; 134: 657-67. [CrossRef] 12. Wong L, Yamasaki G, Johnson RJ, Friedman SL. Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest 1994; 94: 1563-9. [CrossRef]

13. Kelly JD, Haldeman BA, Grant FJ, et al. Platelet-derived growth factor (PDGF) stimulates PDGF receptor subunit dimerization and intersubunit trans-phosphorylation. J Biol Chem 1991; 266: 8987-92.

14. Wang Y, Gao J, Zhang D, Zhang J, Ma J, Jiang H. New insights into the anti-fibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol 2010; 53: 132-44. [CrossRef]

15. Meyer DH, Bachem MG, Gressner AM. Modulation of hepatic lipocyte proteoglycan synthesis and proliferation by Kupffer cell-derived transforming growth factors type beta 1 and type alpha. Biochem Biophys Res Commun 1990; 171: 1122-9. [CrossRef]

16. Win KM, Charlotte F, Mallat A, et al. Mitogenic effect of transforming growth factor-beta 1 on human Ito cells in culture: evidence for mediation by endogenous platelet-derived growth factor. Hepatology 1993; 18: 137-45. [CrossRef]

17. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as modulator of stellate cell and hepatic fibrogenesis. Semin Liver Dis 2001; 21: 351-72. [CrossRef]

18. Brown B, Lindberg K, Reing J, Stolz DB, Badylak SF. The basement membrane component of biologic scaffolds derived from extracellular matrix. Tissue Eng 2006; 12: 519-26. [CrossRef]

19. Breitkopf K, Godoy P, Ciuclan L, Singer MV, Dooley S. TGF-beta/ Smad signaling in the injured liver. Z Gastroenterol 2006; 44: 57-66. [CrossRef]

20. Li Z, Oben JA, Yang S, et al. Norepinephrine regulates hepatic innate immune system in leptin-deficient mice with nonalcoholic steatohepatitis. Hepatology 2004; 40: 434-41. [CrossRef]

21. Sahin H, Trautwein C, Wasmuth HE. Functional role of chemokines in liver disease models. Nat Rev Gastroenterol Hepatol 2010; 7: 682-90. [CrossRef]

22. Schwabe RF, Bataller R, Brenner DA. Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. Am J Physiol Gastrointest Liver Physiol 2003; 285: G949-58. [CrossRef]

23. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011; 195-206. [CrossRef]

24. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009; 50: 957-69. [CrossRef]

25. Ikejima K, Okumura K, Kon K, Takei Y, Sato N. Role of adipocytokines in hepatic fibrogenesis. J Gastroenterol Hepatol 2007; 22 Suppl 1: S87-92. [CrossRef]

26. Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002; 37: 206-13. [CrossRef]

27. Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007; 45: 1366-74. [CrossRef]

28. Mukhopadhyay B, Liu J, Osei-Hyiaman D, et al. Transcriptional regulation of cannabinoid receptor-1 expression in the liver by retinoic acid acting via retinoic acid receptor-gamma. J Biol Chem 2010; 285: 19002-11. [CrossRef]

29. Jeong WI, Osei-Hyiaman D, Park O, et al. Paracrine activation of hepatic CB[1] receptors by stellate cell-derived Endo- cannabinoids mediates alcoholic fatty liver. Cell Metab 2008; 7: 227-35. [CrossRef] 30. De Minicis S, Candelaresi C, Marzioni M, et al. Role of endogenous opioids in modulating HSC activity in vitro and liver fibrosis in vivo. Gut 2008; 57: 352-64. [CrossRef]

31. Ruddell RG, Oakley F, Hussain Z, et al. A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis. Am J Pathol 2006; 169: 861-76. [CrossRef]

32. Zvibel I, Atias D, Phillips A, Halpern Z, Oren R. Thyroid hormones induce activation of rat hepatic stellate cells through increased expression of p75 neurotrophin receptor and direct activation of Rho. Lab Invest 2010; 90: 674-84. [CrossRef]

33. Guo J, Loke J, Zheng F, et al. Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of toll-like receptor 4 to hepatic stellate cell responses. Hepatology 2009; 49: 960-8. [CrossRef] 34. Pradere JP, Troeger JS, Dapito DH, Mencin AA, Schwabe RF. Tolllike receptor 4 and hepatic fibrogenesis. Semin Liver Dis 2010; 30: 232-44. [CrossRef]

35. Liu C, Tao Q, Sun M, et al. Kupffer cells are associated with apoptosis, inflammation and fibrotic effects in hepatic fibrosis in rats. Lab Invest 2010; 90: 1805-16. [CrossRef]

36. Guimaraes EL, Empsen C, Geerts A, van Grunsven LA. Advanced glycation end products induce production of reactive oxygen species via the activation of NADPH oxidase in murine hepatic stellate cells. J Hepatol 2010; 52: 389-97. [CrossRef]

37. Jaeschke H. Inflammation in response to hepatocellular apoptosis. Hepatology 2002; 35: 964-6. [CrossRef]

38. Zhan SS, Jiang JX, Wu J, et al. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology 2006; 43: 435-43. [CrossRef]

39. Jiang JX, Mikami K, Venugopal S, Li Y, Török NJ. Apoptotic body engulfment by hepatic stellate cells promotes their survival by the JAK/STAT and Akt/NF-kappaB-dependent pathways. J Hepatol 2009; 51: 139-48. [CrossRef]

40. Watanabe A, Hashmi A, Gomes DA, et al. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology 2007; 46: 1509-18. [CrossRef]

41. Muhanna N, Tair LA, Doron S, et al. Amelioration of hepatic fibrosis by NK cell activation. Gut 2011; 60: 90-8. [CrossRef]

42. Rosmorduc O, Housset C. Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin Liver Dis 2010; 30: 258-70. [CrossRef]

43. Sims DE. Recent Advances in pericyte biology and implications for health and disease. Can J Cardiol 1991; 7: 431-43.

44. Atta HM. Reversibility and heritability of liver fibrosis: Implications for research and therapy. World J Gastroenterol 2015; 21: 5138-48. [CrossRef]

45. Ramachandran P, Iredale JP. Reversibility of liver fibrosis. Ann Hepatol 2009; 8: 283-91.

46. limuro Y, Nishio T, Morimoto T, et al. Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. Gastroenterol 2003; 124: 445-58. [CrossRef]

47. Iredale JP, Benyon RC, Pickering J et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998; 102: 538-49. [CrossRef]

48. Iredale JP. Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis 2001; 21: 427-36. [CrossRef]

49. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007; 117: 539-48. [CrossRef]

50. Friedman SL. Mechanisms of hepatic fibrosis. Gastroenterology 2008; 134: 1655-69. [CrossRef]

51. Baeck C, Wehr A, Karlmark KR et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 2012; 61: 416-26. [CrossRef]

52. Fallowfield JA, Mizuno M, Kendall TJ, et al. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J Immunol. 2007; 178: 5288-95. [CrossRef]

53. Schnabl B, Purbeck CA, Choi YH, Hagedorn CH, Brenner D. Replicative senescence of activated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibrogenic phenotype. Hepatology 2003; 37: 653-64. [CrossRef]

54. Krizhanovsky V, Yon M, Dickins RA, et al. Senescence of activated stellate cells limits liver fibrosis. Cell 2008; 134: 657-67. [CrossRef] 55. Lujambio A, Akkari L, Simon J, et al. Non-cell- autonomous tumor suppression by p53. Cell 2013; 153: 449-60. [CrossRef]

56. Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013; 499: 97-101. [CrossRef]

57. Hernandez-Gea V, Ghiassi-Nejad Z, Rozenfeld R, et al. Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterol 2012; 142: 938-46. [CrossRef]

58. Hidvegi T, Ewing M, Hale P, et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science 2010; 329: 229-32. [CrossRef]

59. Elpek GÖ. Angiogenesis and liver fibrosis. World J Hepatol 2015; 7: 377-91. [CrossRef]

60. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298-307. [CrossRef]

61. Valfrè di Bonzo L, Novo E, Cannito S, et al. Angiogenesis and liver fibrogenesis. Histol Histopathol 2009; 24: 1323-41.

62. Fernández M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol 2009; 50: 604-20. [CrossRef]

63. Sanz-Cameno P, Trapero-Marugán M, Chaparro M, Jones EA, Moreno-Otero R. Angiogenesis: from chronic liver inflammation to hepatocellular carcinoma. J Oncol 2010; 2010: 272170. [CrossRef] 64. Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterol 2014; 147: 577-94. [CrossRef]

65. Taura K, Iwaisako K, Hatano E, Uemoto S. Controversies over the epithelial-to-mesenchymal transition in liver fibrosis. 2016; 5: E9.

66. Yanguas SC, Cogliati B, Willebrords J, et al. Experimental models of liver fibrosis. Arch Toxicol 2016; 90: 1025-48. [CrossRef]

67. Smith, GP. Animal models for the study of human disease. Elsevier; China: 2013.

68. Beier JI, McClain CJ. Mechanisms and cell signaling in alcoholic liver disease. Biol Chem 2010; 391: 1249-64. [CrossRef]

69. Low TY, Leow CK, Salto-Tellez M, Chung MC. A proteomic analysis of thioacetamide-induced hepatotoxicity and cirrhosis in rat livers. Proteomics 2004; 4: 3960-74. [CrossRef]

70. Verna L, Whysner J, Williams GM. N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. Pharmacol Ther 1996; 71: 57-81. [CrossRef]

71. Aparicio-Bautista DI, Pérez-Carreón JI, Gutiérrez-Nájera N, et al. Comparative proteomic analysis of thiol proteins in the liver after oxidative stress induced by diethylnitrosamine. Biochim Biophys Acta 2013; 1834: 2528-38. [CrossRef]

72. Sánchez-Pérez Y, Carrasco-Legleu C, García-Cuellar C, et al. Oxidative stress in carcinogenesis. Correlation between lipid peroxidation and induction of preneoplastic lesions in rat hepatocarcinogenesis. Cancer Lett 2005; 217: 25-32. [CrossRef]

73. Oh SW, Kim DH, Ha JR, Kim DY. Anti-fibrotic effects of a methylenedioxybenzene compound, CW209292 on dimethylnitrosamine-induced hepatic fibrosis in rats. Biol Pharm Bull 2009; 32: 1364-70. [CrossRef]

74. Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 2006; 87: 1-16. [CrossRef]

75. Rinella ME, Elias MS, Smolak RR, Fu T, Borensztajn J, Green RM. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 2004; 40: 47-51. [CrossRef]

76. Jha P, Knopf A, Koefeler H, et al. Role of adipose tissue in methionine-choline-deficient model of non- alcoholic steatohepatitis (NASH). Biochim Biophys Acta 2014; 1842: 959-70. [CrossRef]

77. Ichimura M, Kawase M, Masuzumi M, et al. High-fat and high-cholesterol diet rapidly induces non- alcoholic steatohepatitis with advanced fibrosis in Sprague-Dawley rats. Hepatol Res 2015; 45: 458-69. [CrossRef]

78. Denda A, Kitayama W, Kishida H, et al. Development of hepatocellular adenomas and carcinomas associated with fibrosis in C57BL/6J male mice given a choline-deficient, L-amino acid-defined diet. Jpn J Cancer Res 2002; 93: 125-32. [CrossRef]

79. Rodríguez-Garay EA, Agüero RM, Pisani G, Trbojevich RA, Farroni A, Viglianco RA. Rat model of mild stenosis of the common bile duct. Res Exp Med (Berl) 1996; 196: 105-16. [CrossRef]

80. Park KC, Park JH, Jeon JY, et al. A new histone deacetylase inhibitor improves liver fibrosis in BDL rats through suppression of hepatic stellate cells. Br J Pharmacol 2014; 171: 4820-30. [CrossRef]

81. Hayashi H, Sakai T. Animal models for the study of liver fibrosis: new insights from knockout mouse models. Am J Physiol Gastrointest Liver Physiol 2011; 300: G729-38. [CrossRef]

82. Larter CZ, Yeh MM. Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol 2008; 23: 1635-48. [CrossRef]

83. Fickert P, Fuchsbichler A, Wagner M, et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterol 2004; 127: 261-74. [CrossRef]

84. Mauad TH, van Nieuwkerk CM, Dingemans KP, et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol 1994; 145: 1237-45.

85. Larter CZ, Yeh MM, Haigh WG, et al. Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease. Obesity (Silver Spring) 2013; 21: 1189-99. [CrossRef]

86. Chisari FV, Filippi P, McLachlan A, et al. Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice. J Virol 1986; 60: 880-7.

87. McCaffrey AP, Nakai H, Pandey K, et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003; 21: 639-44. [CrossRef]

88. Patsenker E, Popov Y, Stickel F, Jonczyk A, Goodman SL, Schuppan D. Inhibition of integrin alpha beta on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology 2008; 135: 660-70. [CrossRef] 89. Lipson KE, Wong C, Teng Y, Spong S. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair 2012; 5: S24. [CrossRef]

90. Bansal R, Nagórniewicz B, Prakash J. Clinical advancements in the targeted therapies against liver fibrosis. Mediators Inflamm 2016; 2016: 7629724. [CrossRef]